heptad
repeat
region
highli
conserv
sequenc
locat
glycoprotein
envelop
virus
form
sixhelix
bundl
structur
import
process
viru
fusion
peptid
deriv
hr
region
virus
shown
inhibit
entri
virus
sarscov
also
predict
region
protein
base
predict
design
peptid
screen
use
hivlucsar
pseudotyp
viru
assay
two
peptid
identifi
potenti
inhibitor
ec
valu
lm
respect
inhibitori
effect
peptid
valid
wildtyp
sarscov
assay
serv
function
probe
dissect
fusion
mechan
sarscov
also
provid
potenti
identifi
potent
inhibitor
sarscov
entri
sever
acut
respiratori
syndrom
sar
lifethreaten
form
atyp
pneumonia
caus
coronavirussar
coronaviru
sarscov
although
first
outbreak
concern
remain
possibl
futur
recurr
despit
earli
success
sarscov
genom
sequenc
later
identif
receptor
neither
efficaci
therapi
prevent
treatment
yet
avail
therefor
effect
drug
need
treatment
prevent
diseas
viral
entri
process
attract
drug
target
block
infect
process
envelop
virus
retroviru
filoviru
ebola
paramyxoviru
mv
measl
viru
coronaviru
mhv
murin
hepat
viru
adopt
similar
molecular
fusion
model
model
believ
envelop
glycoprotein
initi
bind
cell
surfac
receptor
lead
conform
chang
thu
fusion
peptid
expos
insert
target
cell
membran
subsequ
highli
conserv
heptad
repeat
hr
region
glycoprotein
interact
form
sixhelix
bundl
structur
facilit
juxtaposit
viru
cell
membran
lead
membran
fusion
intermedi
state
solubl
synthes
homologu
bind
expos
region
block
format
sixhelix
bundl
thu
inhibit
viru
fusion
target
cell
base
model
entri
inhibitor
success
identifi
virus
ebola
viru
mhv
member
typic
class
envelop
viru
sarscov
presum
use
similar
membran
fusion
mechan
viru
entri
spike
protein
viral
membran
protein
respons
cell
entri
believ
consist
two
subunitsth
surfac
subunit
transmembran
subunit
subunit
identifi
bind
cell
receptor
sarscov
also
suggest
involv
viruscel
fusion
process
model
show
contain
two
heptad
repeat
region
hr
similar
envelop
virus
base
fusion
mechan
describ
use
approach
success
use
studi
envelop
virus
mhv
identifi
potent
inhibitor
viru
entri
seri
peptid
overlap
predict
hr
region
subunit
design
screen
pseudotyp
viru
infect
assay
valid
wildtyp
viru
infect
two
peptid
identifi
abl
inhibit
sarscov
entri
process
cell
line
cell
use
pseudotyp
viru
gener
cell
use
viru
infect
cultur
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
bovin
serum
plasmid
dna
fragment
correspond
design
peptid
amplifi
polymeras
chain
reaction
pcr
full
length
construct
strain
genbank
access
gift
beij
municip
center
diseas
control
prevent
primer
design
incorpor
bamhi
restrict
site
upstream
stop
codon
ecori
site
downstream
target
fragment
fragment
subclon
bamhi
ecori
site
amershampharmacia
biotech
confirm
dna
sequenc
produc
sarscov
pseudoviru
hivluc
codon
optim
sarscov
protein
express
plasmid
pctsh
util
express
purif
peptid
ntermin
gst
fuse
peptid
express
escherichia
coli
strain
purifi
glutathionesepharos
pharmacia
biotech
accord
manufactur
instruct
minor
modif
briefli
cell
grown
ml
luria
broth
lb
contain
ampicillin
agit
od
optic
densiti
reach
isopropylbd
thiogalactosid
iptg
ad
final
concentr
mm
three
hour
later
induc
cell
pellet
resuspend
ml
lysi
buffer
triton
pb
ph
shaken
min
sonic
suspens
centrifug
rpm
min
supernat
collect
bond
glutathionesepharos
min
shake
mixtur
load
column
wash
column
volum
pb
ph
cleav
u
thrombin
h
peptid
elut
ml
pb
collect
purifi
rp
fplc
fraction
contain
peptid
vacuum
dri
overnight
dissolv
pb
last
product
detect
sdspage
trisglycin
gel
concentr
determin
bicinchonin
acid
protein
analysi
micro
bca
assay
kit
pierc
produc
hivlucsar
pseudotyp
viru
lg
hivluc
lg
codon
optim
sarscov
protein
express
plasmid
pctsh
cotransfect
cell
calcium
phosphat
medium
replac
h
posttransfect
h
incub
supernat
contain
pseudotyp
viru
collect
filter
lm
millipores
membran
inhibit
assay
ng
hivlucsar
pseudotyp
viru
incub
serial
dilut
peptid
min
viruspeptid
mixtur
transfer
plate
seed
vero
cell
cell
well
concentr
test
octupl
overnight
incub
medium
replac
sampl
incub
addit
h
cell
lyse
luciferas
activ
measur
wallac
mutilabel
counter
perkinelm
use
luciferas
assay
system
promega
wildtyp
sarscov
infect
inhibit
assay
strain
sarscov
wildtyp
viru
gift
beij
genom
institut
two
hundr
tcid
wildtyp
sarscov
coincub
peptid
differ
concentr
min
mixtur
transfer
plate
eight
well
dilut
incub
h
mtt
assay
perform
describ
previous
briefli
dimethylthiazol
diphenyltetrazolium
mtt
mgml
sigmaaldrich
ad
well
incub
h
medium
well
replac
dmso
plate
stay
room
temperatur
min
color
develop
read
biorad
model
elisa
reader
use
test
wavelength
nm
refer
wavelength
nm
cd
spectra
analysi
cd
spectra
scan
peptid
lm
pb
record
jobin
yvon
cd
spectromet
use
path
length
spectrum
averag
four
scan
correct
subtract
spectrum
buffer
solut
absenc
proteinasepeptid
record
ident
condit
scan
rang
nm
obtain
take
data
point
everi
nm
integr
time
bandwidth
nm
secondari
structur
content
calcul
use
program
http
identifi
heptad
repeat
hr
region
within
protein
sarscov
util
learncoilvmf
program
predict
coiledcoil
region
graphic
output
result
shown
fig
predict
show
subunit
ectodomain
sarscov
like
mhv
contain
two
hr
domain
region
residu
region
residu
locat
near
transmembran
domain
amino
acid
residu
upstream
design
peptid
correspond
region
order
quickli
effect
identifi
potent
inhibitor
class
envelop
virus
effect
peptid
entri
inhibitor
mostli
deriv
c
termin
helix
region
thu
design
peptid
tabl
cover
region
five
peptid
overlap
region
tabl
produc
long
peptid
use
recombin
e
coli
express
system
abl
provid
peptid
product
larg
quantiti
low
cost
recombin
peptid
express
e
coli
purifi
chromatographi
product
analyz
sdspage
fig
show
purifi
exampl
peptid
detect
entri
inhibit
activ
panel
peptid
hivlucsar
pseudotyp
viru
two
peptid
found
antivir
activ
fig
show
locat
ntermin
residu
fig
ec
valu
lm
correspond
region
fig
ec
valu
lm
peptid
show
littl
antiviru
activ
fig
test
inhibitori
effect
wildtyp
sarscov
use
mtt
assay
previous
describ
also
show
inhibit
activ
wildtyp
viru
infect
ec
valu
lm
respect
fig
result
similar
pseudotyp
viru
assay
none
tabl
sequenc
peptid
deriv
region
sarscov
spike
protein
peptid
show
antiviru
activ
data
shown
screen
pseudotyp
viru
assay
found
effect
inhibit
viral
entri
wherea
wildtyp
assay
differ
shown
less
distinct
discrep
may
attribut
sensit
quantit
natur
pseudotyp
viru
assay
analyz
inhibit
effect
viru
entri
singleround
infect
use
quantit
luciferas
assay
system
compar
wildtyp
viru
assay
peptid
inhibitor
bind
fusogen
intermedi
interact
ahelix
investig
whether
also
ahel
structur
whether
two
peptid
abl
form
oligomer
complex
circular
dichroism
cd
use
studi
second
structur
complex
cd
spectra
equimolar
mixtur
two
peptid
shown
fig
spectra
mixtur
show
clear
neg
peak
nm
small
neg
peak
nm
thu
suggest
atypicalhelix
characterist
studi
found
none
differ
peptid
correspond
region
higher
inhibit
activ
result
contrast
envelop
virus
mhv
whose
peptid
region
outperform
inhibit
viru
fusion
envelop
viru
fusion
model
region
form
inner
trimer
coiledcoil
core
surround
three
helic
region
outsid
way
interact
also
molecul
propos
poor
inhibitor
virus
form
selfassoci
oligom
aggreg
isol
therefor
interf
abil
effici
block
format
sixhelix
bundl
case
sarscov
potent
inhibit
activ
may
correl
atypicalhelix
structur
cd
spectra
show
fig
conform
low
coiledcoil
tendenc
might
inhibit
selfassoci
oligomer
thu
increas
inhibit
potenc
analysi
structur
consist
recent
report
liu
et
al
report
major
local
helic
content
downstream
residu
typic
ahelix
structur
howev
found
similar
show
viral
entri
inhibit
activ
similarli
case
mhv
demonstr
region
typic
ahelix
structur
show
low
inhibitori
activ
evid
support
proposit
report
peptid
hiv
could
induc
format
coiledcoil
core
therefor
suggest
presenc
endogen
region
may
undergo
conform
chang
atypicalhelix
structur
typicalhelix
structur
bind
region
block
fusion
intermedi
state
although
design
seri
peptid
overlap
region
one
peptid
identifi
inhibit
entri
sarscov
low
inhibitor
activ
recent
report
peptid
correspond
stronger
ahel
spectrum
also
show
low
inhibitori
activ
therefor
potent
inhibitor
entri
sarscov
still
identif
addit
screen
peptid
found
slight
differ
peptid
could
affect
inhibitori
activ
exampl
peptid
three
amino
acid
show
inhibit
activ
moreov
peptid
show
activ
inhibit
viru
entri
addit
two
amino
acid
ctermin
peptid
identifi
inhibit
activ
liu
et
al
possibl
addit
delet
sever
amino
acid
may
chang
conform
structur
peptid
consequ
influenc
inhibitori
effect
base
refin
map
peptid
detect
chang
conform
inhibitori
activ
order
identifi
possibl
correl
summari
data
suggest
region
crucial
entri
sarscov
support
assumpt
sarscov
may
employ
fusion
mechan
virus
class
envelop
protein
use
function
probe
studi
fusion
process
sarscov
may
final
lead
find
potent
inhibitor
peptid
sarscov
fig
secondari
structur
complex
circular
dichroism
cd
analysi
cd
spectra
peptid
analyz
pb
spectra
solid
line
dash
line
show
clear
neg
peak
nm
spectra
complex
dot
line
show
clear
neg
peak
nm
small
neg
peak
nm
indic
ahelix
characterist
